Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six universities including Oxford have been awarded a total of £4.3m by the Medical Research Council (MRC) to grow and develop the UK’s research base in dementia science.

Zam Cader, leader of the Oxford Momentum Award

The Momentum awards, designed to support the UK Dementia Research Institute (DRI), will help open new research avenues which could transform the potential of dementia research in the UK. The awards represent the first steps in establishing the capabilities for the DRI, which is being funded through a combined investment of £250m from the MRC and founding charity partners, the Alzheimer’s Society and Alzheimer’s Research UK. The DRI is expected to be up and running by 2019.

The DRI will be the biggest single investment into dementia research the UK has ever seen and we are proud to start building the foundation for it now. These transformative awards will create exciting new opportunities across the dementia research landscape and provide impetus to allow the Institute to start making its mark as soon as it is launched.
- Dr Rob Buckle, director of science programmes at the MRC

Each award will enhance overall dementia research capacity in the UK and, crucially, will accelerate the recruitment of research leaders and ‘rising stars’ from both within and outside of the UK. The funding will also help current researchers develop promising connections between different research disciplines to bring new understanding to the field, as well as exploit emerging scientific opportunities and explore new approaches to fight the disease.

The Oxford Momentum Award is led by Zam Cader, who will be developing methods to better understand the epigenetics of microglia interactions in dementia. The other project leads for this multi-disciplinary programme are Sally Crowley, Francesca Nicholls, Florian Plattner and Caleb Webber.  The four projects are designed to develop key capabilities in the provision of human brain cell types, cell imaging analysis and targeting signalling pathways, and will include recruitment back to the UK of a researcher who currently holds a faculty appointment in the US.

Similar stories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Clinical Neurology Research

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Low-cost ventilator wins at E&T Innovation Awards

Anaesthetics Award Coronavirus

The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.